References
- Cancer Facts and Figures 2008. American Cancer Society. Atlanta, GA: American Cancer Society, 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf [Last accessed: 10 September 2008]
- Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31
- Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9
- Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-44
- Curti BD. Renal cell carcinoma. JAMA 2004;292:97-100
- Menzel T, Bergmann L. Treatment strategies in metastatic renal cell carcinoma. Onkologie 1999;22:472-6
- Nexavar (sorafenib) Full Prescribing Information. Bayer HealthCare. Available at: http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf [Last accessed: 17 November 2008]
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell-renal-cell carcinoma. N Engl J Med 2007;356:125-34
- Mulder SF, van Spronsen DJ, De Mulder PH. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?. Onkologie 2007;30:260-4
- Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
- Sutent (sunitinib malate) U.S. Physician Prescribing Information. Pfizer. Available at: http://media.pfizer.com/files/products/uspi_sutent.pdf [Last accessed on 17 November 2008]
- Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24
- Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
- Avastin (bevacizumab) Full Prescribing Information. Genentech. Available at: http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp [Last accessed: 17 November 2008]
- DeMario MD, Ratain, MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67
- Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64:S4-7
- SEER Stat Fact Sheets; Cancer: Kidney and Renal Pelvis. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html [Last accessed 17 November 2008]
- Bukowski RM, Kabbinavar FF, Figlin, RA. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41
- NCCN Clinical Practice Guidelines in Oncology; Kidney Cancer, V.1.2009. National Comprehensive Cancer Network
- Ljungberg B, Hanbury DC, Kucyk AS, et al. Guidelines on renal cell carcinoma. European Association of Urology, 2007
- Rini BI, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?. Oncology 2008;22:388-480
- Duh MS, Weiner JR, Lefebvre P, et al. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008;24:967-7